Growth Metrics

Silence Therapeutics (SLN) Change in Account Payables (2020 - 2024)

Silence Therapeutics' Change in Account Payables history spans 5 years, with the latest figure at -$862735.3 for Q3 2024.

  • On a quarterly basis, Change in Account Payables fell 824.57% to -$862735.3 in Q3 2024 year-over-year; TTM through Sep 2024 was $3.2 million, a 189.91% increase, with the full-year FY2023 number at $54610.7, down 96.95% from a year prior.
  • Change in Account Payables hit -$862735.3 in Q3 2024 for Silence Therapeutics, down from $5.9 million in the prior quarter.
  • Over the last five years, Change in Account Payables for SLN hit a ceiling of $5.9 million in Q2 2024 and a floor of -$4.2 million in Q1 2022.
  • Historically, Change in Account Payables has averaged $688904.8 across 5 years, with a median of $939552.0 in 2023.
  • The widest YoY moves for Change in Account Payables: up 481.42% in 2024, down 824.57% in 2024.
  • Tracing SLN's Change in Account Payables over 5 years: stood at $2.9 million in 2020, then plummeted by 37.27% to $1.8 million in 2021, then plummeted by 247.3% to -$2.7 million in 2022, then soared by 134.77% to $939552.0 in 2023, then crashed by 191.82% to -$862735.3 in 2024.
  • Business Quant data shows Change in Account Payables for SLN at -$862735.3 in Q3 2024, $5.9 million in Q2 2024, and -$2.7 million in Q1 2024.